Remibrutinib Treatment Improves Itch and Sleep in Chronic Spontaneous Urticaria Patients: Phase 2b Study Results

被引：0
|
作者：
Hsu, Connie [1 ]
Snyder, Robert [2 ]
Clore, Lee [3 ]
Jain, Vipul [4 ]
Gimenez-Arnau, Ana [5 ]
Lheritier, Karine [6 ]
Walsh, Pauline [7 ]
Haemmerle, Sibylle [6 ]
Wells, Michael [8 ]
Nikolaev, Ivan [6 ]
Maurer, Marcus [9 ,10 ,11 ,12 ]
机构：
[1] Res Solut Arizona, Phoenix, AZ USA
[2] Riverchase Dermatol, Pembroke Pines, FL USA
[3] Allergy & Asthma Specialists PSC, Owensboro, KY USA
[4] McMaster Univ, Div Clin Immunol & Allergy, Dept Med, Hamilton, ON, Canada
[5] Univ Pompeu Fabra, Hosp Mar IMIM, Dept Dermatol, Barcelona, Spain
[6] Novartis Pharma AG, Basel, Switzerland
[7] Novartis Ireland Ltd, Dublin, Ireland
[8] Novartis Pharmaceut, E Hanover, NJ USA
[9] Charit Univ Med Berlin, Inst Allergol, Urticaria Ctr Reference & Excellence UCARE, Berlin, Germany
[10] Free Univ Berlin, Berlin, Germany
[11] Humboldt Univ, Berlin, Germany
[12] Fraunhofer Inst Translatio, Frankfurt, Germany
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
42939
引用
收藏
页码：AB82 / AB82
页数：1
相关论文
共 50 条
  • [21] DITCH THE ITCH: TREATMENT AND MALIGNANCY WORKUP IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA
    Yellin, Shira H.
    Sundaresh, Shyam
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2023, 38 : S586 - S586
  • [22] Ligelizumab improves sleep interference and disease burden in patients with chronic spontaneous urticaria
    Gimenez-Arnau, Ana
    Maurer, Marcus
    Bernstein, Jonathan
    Staubach, Petra
    Barbier, Nathalie
    Hua, Eva
    Severin, Thomas
    Joubert, Yolandi
    Janocha, Reinhold
    Balp, Maria-Magdalena
    CLINICAL AND TRANSLATIONAL ALLERGY, 2022, 12 (02)
  • [23] Ligelizumab in adolescents with chronic spontaneous urticaria: Results of a dedicated phase 2b randomized clinical trial supported with pharmacometric analysis
    Staubach, Petra
    Alvaro-Lozano, Montserrat
    Sekerel, Bulent Enis
    Maurer, Marcus
    Ben-Shoshan, Moshe
    Porter, Miriam
    Hua, Eva
    Ji, Yan
    Burciu, Alis
    Savelieva, Marina
    Severin, Thomas
    Drollmann, Anton
    Bienczak, Andrzej
    PEDIATRIC ALLERGY AND IMMUNOLOGY, 2023, 34 (07)
  • [24] High rate of complete response achieved with ligelizumab in patients with moderate to severe chronic spontaneous urticaria throughout the phase 2b core study
    Bernstein, Jonathan A.
    Maurer, Marcus
    Gimenez-Arnau, Ana
    Soong, Weily
    Sitz, Karl
    Hua, Eva
    Barbier, Nathalie
    Barve, Avantika
    Severin, Thomas
    Janocha, Reinhold
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB137 - AB137
  • [25] Dupilumab Significantly Reduces Itch and Hives in Patients With Chronic Spontaneous Urticaria: Results From a Phase 3 Trial (LIBERTY-CSU CUPID Study A)
    Maurer, Marcus
    Casale, Thomas
    Saini, Sarbjit
    Ben-Shoshan, Moshe
    Amin, Nikhil
    Radin, Allen
    Akinlade, Bolanle
    Fan, Chunpeng
    Bauer, Deborah
    Laws, Elizabeth
    Mannent, Leda
    Stjepanovic, Aleksandra
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (02) : AB312 - AB312
  • [26] Personalized omalizumab treatment improves clinical benefit in patients with chronic spontaneous urticaria
    Niemeyer-van der Kolk, Tessa
    van Maaren, Maurits S.
    van Doorn, Martijn B. A.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2018, 142 (06) : 1992 - 1994
  • [27] Complete freedom from chronic spontaneous urticaria signs and symptoms is associated with sleep and dermatology quality-of-life improvements: Data from the phase 2b ligelizumab study
    Bernstein, Jonathan A.
    Gimenez-Arnau, Ana
    Hide, Michihiro
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB35 - AB35
  • [28] Efficacy of Remibrutinib in Patients With Chronic Spontaneous Urticaria With or Without Prior Exposure to Biologics in the Phase 3 REMIX-1 and REMIX-2 Studies
    Mosnaim, Giselle
    Gimenez-Arnau, Ana
    Hide, Michihiro
    Lebwohl, Mark
    Maurer, Marcus
    Metz, Martin
    Saini, Sarbjit
    Sussman, Gordon
    Haemmerle, Sibylle
    Lheritier, Karine
    Martzloff, El-Djouher
    Seko, Noriko
    Wang, Pengpeng
    Gogate, Shalia
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB369 - AB369
  • [29] Results of the Eteplirsen Phase 2b and Phase 2b Extension Study in Duchenne Muscular Dystrophy
    Kaye, Ed
    NUCLEIC ACID THERAPEUTICS, 2012, 22 (06) : A13 - A13
  • [30] Ligelizumab as add-on therapy for patients with H1-antihistamine-refractory chronic spontaneous urticaria: Primary results of a placebo- and active-controlled phase 2b dose finding study
    Maurer, M.
    Gimenez-Arnau, A.
    Sussman, G.
    Loeffler, J.
    Barve, A.
    Severin, T.
    Janocha, R.
    ALLERGY, 2018, 73 : 837 - 837
12345